OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

2014 Ann Schreiber Mentored Investigators Award Recipient – Nima Aghaeepour, PhD

Nima Aghaeepour, PhD
Stanford University
Computationally-guided Characterization of Therapy-resistant Ovarian Tumors

aghaeepour head cropped

Project Summary
Although the majority of patients who present with an aggressive ovarian tumor respond well to initial treatment, 70-90% of them will relapse and die of their disease. One explanation for this is the postulated existence of intrinsically therapy-resistant tumor-initiating cells (TICs) that can regenerate a complete tumor. Because these cells are often rare, standard technologies may be unable to detect them. Mass cytometry is a transformative new proteomics technology that enables characterization of rare and heterogeneous cell populations.

This project makes specific use of several technologies based on the mass cytometry platform to systematically identify and disrupt the signaling pathways that contribute to tumor-initiation at a single-cell-level. We will start by a comprehensive profiling of a wide range of tumors and cell lines. Next, we will use a correlative study against clinical parameters (e.g., time to recurrence), tumor initiation activity, and signaling pathways of interest, to identify candidate TIC populations. Then, an algorithm will mine our high-dimensional measurements of surface markers to identify optimized isolation strategies for functional validation of the TIC candidates in vivo. Finally, we will use a high-throughput mass cytometry technique to screen a wide range of standard-of-care and investigational compounds, including pathway-targeted inhibitors, on the purified TICs. This approach has the unique capability to measure drug responses in terms of tens of phenotypic and signaling pathway on millions of independent cells. This can enable the design of synergistic therapies for targeting multiple TIC compartments with minimal toxicity.

Bio
Nima Aghaeepour, Ph.D. is currently a postdoctoral fellow with Prof. Garry Nolan at Stanford University and the Scholar of the International Society for Advancement of Cytometry. Dr. Aghaeepour completed his B.Sc. in Computer Science at University of Tehran with a focus on both robotics and systems biology. His Ph.D. training in the University of British Columbia was supported by graduate awards from the Canadian Institute of Health Research’s Strategic Training Program in Bioinformatics and the University of British Columbia’s 4Y Award. Dr. Aghaeepour’s current research is focused on computational analysis of signaling abnormalities in ovarian tumors at a single cell level using flow and mass cytometry.

 

This grant was made possible by a donation from the UC Office of the President Tobacco-Related Disease Research Program.